It's almost time...🕑 We’re excited to be an official Media Partner of #PharmSci360! Keep your eyes peeled for exclusive interviews with conference presenters, plus our conference report highlighting some of the exciting talks taking place throughout the week!

Check out our 2-minute video on ‘Addressing ligand binding assay challenges in ADC analysis’ as part of our latest In the Zone with @GyrosProteinTec!  Watch now >>> hubs.ly/Q04z-PPg0

Successful #biomarker programs start with alignment 🤝   Whether you're an experienced Sponsor or new to biomarker assay development, collaboration between CROs and Sponsors is critical. This Spotlight shares both perspectives, revealing how clear communication, shared understanding of context of use, and integrated PK-biomarker strategies lead to faster timelines and better outcomes.  Find all of our resources here, in partnership with @Resolian_ >>> hubs.ly/Q04zg2fM0

How do you de-risk mRNA-LNP therapeutics? Our 4 November webinar covers integrated strategies for biodistribution, bioanalysis and safety assessment to help you make confident IND-enabling decisions. Register >>> hubs.ly/Q04BghNp0

⏱️ When should you assess immune responses for LNP products? The answer: throughout the entire development lifecycle!  From early discovery and formulation screening through to preclinical studies and clinical trials, a risk-based approach tailored to your product's mechanism of action and indication ensures comprehensive safety and efficacy evaluation.  Read more here >>> hubs.ly/Q04xMF-v0

On October 1, Immunologix Laboratories hosted the 3rd Annual Bioanalysis Symposium: The Science of Fit-For-Purpose Bioanalysis, at Le Méridien Boston Cambridge. The program spanned three sessions centered on a single question that ran through the day: how to design and validate bioanalytical strategies that answer the specific clinical question a therapeutic program needs to address, rather than defaulting to legacy assay conventions. Read our highlights from the event ⭐👉 Highlights from the 3rd Annual Immunologix Bioanalysis Symposium - Bioanalysis Zone (hubs.ly/Q04B_87q0)

This might be our biggest prize draw yet…  Complete our 5-min #survey and you could be in with the chance to win one of two UDS $100 vouchers.  Move quickly before it closes >>> hubs.ly/Q04zg4LY0

There’s just a few days to go before the BZ team head to #PharmSci360! Watch this space for our highlights from the event, including interviews with conference speakers📽️ We're so excited to meet you 👋

Read this Perspective: ‘Biomarker validation – where are we today?’ today!  Check out the Perspective, as part of our Spotlight with @Resolian_, here >>>  hubs.ly/Q04zq1ln0

What if you could reduce bioanalytical delays and speed up development timelines? Discover how leading CROs are doing it with connected, end-to-end workflows and digital technologies. Join us: hubs.ly/Q04Bdn860

Are decades-old immunogenicity testing paradigms still fit for today’s therapeutic landscape, or is it time for a more scientifically relevant, risk-based approach?  Read the #WhitePaper from @IQVIA_global to learn more about immunogenicity testing >>>   hubs.ly/Q04zf-zx0

Alvotech, a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the US Food and Drug Administration has approved a new manufacturing process for SIMLANDI® (adalimumab-ryvk), Alvotech’s biosimilar to Humira® (adalimumab), for the treatment of chronic inflammatory and autoimmune conditions ➡️ hubs.ly/Q04BSsNX0

Attending #PharmSci360 2026? The Bioanalysis Zone team will be at booth 829 to chat with you about the Bioanalysis journal and Digital Hub and how you can get involved with our content📘  Reach out to book a meeting with us >>> [email protected] Plus, as an official Media Partner, we will be filming content with conference speakers so be sure to stay tuned 👀📽️ @aapscomms

Drug metabolism and pharmacokinetics (DMPK) play a critical role in advancing drug candidates from discovery to the clinic.  In this comprehensive Guide from Waters, discover how modern DMPK strategies can help reduce development risk, accelerate decision-making and build confidence in regulatory submissions.   Read now >>> hubs.ly/Q04ySFWG0

Build pharmacokinetic and immunogenicity assays without custom critical reagents! Discover how on 27 Oct, 14:00 GMT (10:00 EDT) with BioAgilytix. Join the webinar >>> hubs.ly/Q04zwtc70

What are the five most common LBA method development failures for ADCs? How can you avoid them? What core assays are required for regulatory submission?  We've got all the answers in this #infographic with @GyrosProteinTec.  Download now for free >>> hubs.ly/Q04z-PNc0

AAPS has released the program for the 2026 PharmSci 360 event taking place from 25–28 October at the Ernest N. Morial Convention Center (New Orleans, LA, USA). Symposia, keynotes, speaker spotlights, poster sessions, hot topic presentations and rapid-fire talks taking place at PharmaSci 360 will examine the current trends in pharmaceutical sciences. With five main tracks, topics include immunogenicity assessment for emerging modalities, patient-centric and decentralized sampling, ultra-sensitive and multiplexed bioanalysis, strategies for new approach methodologies (NAMs) and organ-on-chip, and the ever-present battle against regulatory ‘gray areas’. Here are some of the presentations and plenaries our Editors are looking forward to! ➡️ AAPS PharmSci 360 2026: what can conference attendees look forward to? - Bioanalysis Zone (hubs.ly/Q04BH2gb0)

Humanoid robot development in general is picking up speed.  June 2026 brought us something straight out of a sci-fi film: humanoid robots mastering pipettes, beakers and Erlenmeyer flasks on live TV. Government-sponsored research centers are now training these mechanical scientists for real-world lab work. But what part does this have to play in the bioanalytical industry? Ming Li from Alexion, AstraZeneca Rare Disease, provides a few thoughts ➡️ hubs.ly/Q04z0ntP0

The final White Paper in the vaccine LBA trilogy has been published in Bioanalysis, completing a 5-year endeavor to create an overarching vaccine assay validation document that began in early 2021. The series is the outcome of a collaborative effort by a working group of experts from 16 global vaccine manufacturers, national regulatory authorities, and a nonprofit global-health foundation convened under the Workshop on Recent Issues in Bioanalysis (WRIB). Part 2 offers clear guidance on the iterative process of LBA development, essential for ensuring long-term assay performance and regulatory confidence. More information here 👉 Development of LBA to support vaccine immunogenicity studies - Bioanalysis Zone (hubs.ly/Q04Bz3vp0)

Activin E – a liver-derived member of the transforming growth factor-ß superfamily and a key regulator of adipose tissue metabolism – has attracted considerable attention in recent years. In this #CaseStudy from @Resolian_ you’ll gain insight into how Activin E measurements can help give biologically meaningful assessment of target engagement and biological activity.   Find out more here >>>  hubs.ly/Q04zp-pm0